Down 11% in a year, 5 big-money filings in 90 days.
NSE close · 17 Sep
Down 11% in a year, 5 big-money filings in 90 days.
NSE close · 17 Sep
Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.
Loading quarterly results.
Buy
Based on 36 analysts.
Loading the consensus price target.
Loading financial history.
-1.6% vs price
-3.5% vs price
-0.9% vs price
Fund added31 Jul
1,329 shares
Nothing filed yet.
1Public Shareholders
70.79%
2Promoter and Promoter Group
29.21%
3Yusuf Khwaja Hamied
18.69%
4Lici Ulip-Growth Fund
9.75%
5Sophie Ahmed
5.71%
6HDFC Trustee Company Ltd-HDFC Flexi Cap Fund
4.48%
7M K Hamied
3.46%
8SBI Nifty 50 Equal Weight Index Fund
3.24%
9ICICI Prudential Equity Savings Fund
2.36%
10Nippon Life India Trustee Ltd-A/C Nippon India ARB
1.96%
11DSP Nifty 50 Index Fund
1.90%
12Parag Parikh Arbitrage Fund
1.87%